title: Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation.
abstract: We retrospectively analyzed the factors that affect serum cyclosporine (CsA) concentrations up to day 14 after allogeneic hematopoietic stem cell transplantation (HSCT). In all, 103 transplant recipients who received MTX and CsA for acute GVHD prophylaxis were analyzed. No significant relationships between serum CsA concentrations and gender, age, serum creatinine levels, AST/ALT levels, or antibiotic/fluconazole administration were found by comparing median CsA concentrations or by using longitudinal or regression multivariate analyses. However, the mean of the median serum CsA concentration in patients (n=54) receiving the regimen containing cyclophosphamide (CY) (149.7 ng/ml; 95% confidence interval (CI): 132.1-167.4) was significantly (P<0.0001) lower than that in patients (n=49) receiving the non-CY regimen (217.3 ng/ml; 95% CI: 198.9-235.6). Longitudinal analysis and regression multivariate analysis showed that only administration of CY had a significant effect on the serum CsA concentration. Our results suggest that administration of CY during conditioning can reduce the effects on serum CsA concentrations during the 2 weeks following HSCT. The mechanism of this effect is not clear, but it may be due to the autoinduction of CY.
authors: Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. nagamura@ims.u-tokyo.ac.jp
authors: F
authors: F
authors: Nagamura
authors: T
authors: T
authors: Takahashi
authors: M
authors: M
authors: Takeuchi
authors: T
authors: T
authors: Iseki
authors: J
authors: J
authors: Ooi
authors: A
authors: A
authors: Tomonari
authors: K
authors: K
authors: Uchimaru
authors: S
authors: S
authors: Takahashi
authors: A
authors: A
authors: Tojo
authors: K
authors: K
authors: Tani
authors: S
authors: S
authors: Asano
mesh_terms: D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000494:pharmacology*; D016572:Cyclosporine / Q000037:antagonists & inhibitors / Q000097:blood*; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016572:Cyclosporine; D003520:Cyclophosphamide